Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTOR: Rapamycin and Everolimus Study Towards Older Rejuvenation
NCT06658093Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sirolimus and everolimus in aging (7 arms), sponsored by UT Health San Antonio. Primary endpoints: Pharmacokinetics of mTOR inhibitor in blood at 12 months, PD measure of inhibition of mTOR activity in blood cells - p-rpS6 at 12 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
sirolimuseverolimus
03
Conditions
aging
Beyond the preview
Go deeper on NCT06658093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658093.